Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Pacific Biosciences of California stock | $25.94

Own Pacific Biosciences of California stock in just a few minutes.

Fact checked

Pacific Biosciences of California, Inc is a diagnostics & research business based in the US. Pacific Biosciences of California shares (PACB) are listed on the NASDAQ and all prices are listed in US Dollars. Pacific Biosciences of California employs 404 staff and has a trailing 12-month revenue of around USD$79.7 million.

How to buy shares in Pacific Biosciences of California

  1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
  3. Search for Pacific Biosciences of California. Find the stock by name or ticker symbol: PACB. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Pacific Biosciences of California reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. At last close price of USD$25.94, weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Pacific Biosciences of California, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of Pacific Biosciences of California. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

Pacific Biosciences of California share price

Use our graph to track the performance of PACB stocks over time.

Pacific Biosciences of California shares at a glance

Information last updated 2020-12-28.
Latest market closeUSD$25.94
52-week rangeUSD$2.2 - USD$29.71
50-day moving average USD$18.8609
200-day moving average USD$10.1514
Wall St. target priceUSD$17.4
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) USD$-0.753

Buy Pacific Biosciences of California shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee
Sofi Invest
Stocks, ETFs, Cryptocurrency
A free way to invest in stocks, ETFs and crypto.
Interactive Brokers
Stocks, Forex
$0 + $0.65/contract, $1 minimum
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
Stocks, ETFs
Stocks, Options, ETFs, Cryptocurrency
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Stocks, Bonds
$0 for US stocks
Stocks, Options, ETFs
Trade stocks on the US, Hong Kong, Shanghai and Shenzhen markets.

Compare up to 4 providers

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Pacific Biosciences of California stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Pacific Biosciences of California price performance over time

Historical closes compared with the close of $25.94 from 2020-12-31

1 week (2021-01-11) N/A
1 month (2020-12-22) -3.75%
3 months (2020-10-18) N/A
6 months (2020-07-18) N/A
1 year (2020-01-18) N/A
2 years (2019-01-18) N/A
3 years (2018-01-18) N/A
5 years (2016-01-18) N/A

Pacific Biosciences of California financials

Revenue TTM USD$79.7 million
Gross profit TTM USD$34.6 million
Return on assets TTM -27.17%
Return on equity TTM -50.55%
Profit margin -57.25%
Book value $0.72
Market capitalisation USD$5.2 billion

TTM: trailing 12 months

Shorting Pacific Biosciences of California shares

There are currently 13.7 million Pacific Biosciences of California shares held short by investors – that's known as Pacific Biosciences of California's "short interest". This figure is 5.1% down from 14.4 million last month.

There are a few different ways that this level of interest in shorting Pacific Biosciences of California shares can be evaluated.

Pacific Biosciences of California's "short interest ratio" (SIR)

Pacific Biosciences of California's "short interest ratio" (SIR) is the quantity of Pacific Biosciences of California shares currently shorted divided by the average quantity of Pacific Biosciences of California shares traded daily (recently around 4.2 million). Pacific Biosciences of California's SIR currently stands at 3.28. In other words for every 100,000 Pacific Biosciences of California shares traded daily on the market, roughly 3280 shares are currently held short.

However Pacific Biosciences of California's short interest can also be evaluated against the total number of Pacific Biosciences of California shares, or, against the total number of tradable Pacific Biosciences of California shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Pacific Biosciences of California's short interest could be expressed as 0.06% of the outstanding shares (for every 100,000 Pacific Biosciences of California shares in existence, roughly 60 shares are currently held short) or 0.0673% of the tradable shares (for every 100,000 tradable Pacific Biosciences of California shares, roughly 67 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Pacific Biosciences of California.

Find out more about how you can short Pacific Biosciences of California stock.

Pacific Biosciences of California share dividends

We're not expecting Pacific Biosciences of California to pay a dividend over the next 12 months.

Pacific Biosciences of California share price volatility

Over the last 12 months, Pacific Biosciences of California's shares have ranged in value from as little as $2.2 up to $29.71. A popular way to gauge a stock's volatility is its "beta".

PACB.US volatility(beta: 1.12)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Pacific Biosciences of California's is 1.1192. This would suggest that Pacific Biosciences of California's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).

Pacific Biosciences of California overview

Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing systems to resolve genetically complex problems. Its single molecule real-time (SMRT) sequencing technology enables single molecule real-time detection of biological processes. The company also provides consumable products, including SMRT cells, as well as various reagent kits designed for specific workflow such as template preparation to convert DNA into SMRTbell double-stranded DNA library formats including molecular biology reagents, such as ligase, buffers and exonucleases. In addition, it provides binding kits, such as modified DNA polymerase used to bind SMRTbell libraries to the polymerase in preparation for sequencing; and sequencing kits comprises reagents required for on-instrument, real-time sequencing, including the phospholinked nucleotides. The company serves research institutions; commercial laboratories; genome centers; clinical, government, and academic institutions; genomics service providers; pharmaceutical companies; and agricultural companies. It markets its products through a direct sales force in North America and Europe, as well as through distribution partners in Asia, Europe, the Middle East, Africa, and Latin America. Pacific Biosciences has collaboration with Asuragen to develop assays for carrier screening and other applications based on SMRT sequencing technology and AmplideX PCR chemistry; Invitae Corporation focuses on the investigation of clinically relevant molecular targets for use in the development of advanced diagnostic testing for epilepsy. The company was formerly known as Nanofluidics, Inc. and changed its name to Pacific Biosciences of California, Inc. in 2005. Pacific Biosciences of California, Inc. was founded in 2000 and is headquartered in Menlo Park, California.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site